Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / TNFAIP6

TNFAIP6

Basics

Aliases:
This biomarker is also known as:
  • TSG-6,
  • Hyaluronate-binding protein,
  • TNF alpha-induced protein 6,
  • tumor necrosis factor-stimulated gene-6 protein,
  • tumor necrosis factor, alpha-induced protein 6,
  • tumor necrosis factor-inducible gene 6 protein,
  • Tumor necrosis factor-inducible gene 6 protein,
  • P98066,
  • TSG6,
  • TNF-stimulated gene 6 protein,

View in BioMuta

Description…

TNFAIP6 is a secretory protein that contains a hyaluronan-binding domain, and thus is a member of the hyaluronan-binding protein family. It is possibly involved in cell-cell and cell-matrix interactions during inflammation and tumorigenesis. Enhanced levels of this protein are found in the synovial fluid of patients with osteoarthritis and rheumatoid arthritis.

Attributes

QA State: Curated
Type: Protein
Short Name:
HGNC Name: TNFAIP6

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Ovary

Attributes

Phase: Two
QA State: Under Review

Overview

TNFAIP6 (TSG6) localized to vascular-like structures in ovarian cancer but not in normal ovaries.

Performance Comment

TNFAIP6 (TSG6) was one of 13 genes out of 50 selected for further validation in PMID:21617380. Average expression of TNFAIP6 was significantly higher in epithelial ovarian cancer tumors than any other normal tissue tested.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

New Funding Opportunity: Biomarker Development Laboratories for the Early Detection Network: Applications Due May 23

Update: Pre-application webinar information now available.

The National Cancer Institute's Division of Cancer Prevention has released a new funding opportunity to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers.

The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this funding opportunity) should be focused on one or more of the following cancers: breast, prostate and other genitourinary organs, or lung. In addition, cancers with rapidly rising incidence rates, e.g., endometrial, hepatocellular, kidney, thyroid, oropharyngeal cancers, and/or cancers with unique etiology, e.g., mesothelioma, will be considered.

The newly funded units of the Early Detection Research Network will be announced later in April. Successful applicants have already been notified. Those researchers who were not successful during the last round of applications are encouraged to apply to this opportunity.